Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: hGH (Human Growth Hormone) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women

NCT02272647
View directory record Official record
Conditions
Healthy
Interventions
IM Saline Placebo (0.25 ml), IM Estradiol valerate (2.5 mg), IM Saline Placebo (0.5 ml), IM Estradiol valerate (5.0 mg), Oral Micronized Progesterone, Oral Placebo, Ghrelin (0.3 ug/kg), Medroxyprogesterone - Acetate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Jul 21, 2026, 11:43 PM EDT
Completed Not applicable Interventional

Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)

NCT00108225
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LoBag Diet - test phase, LoBAG Diet - control phase
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
55 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Jul 21, 2026, 11:43 PM EDT
Completed Not applicable Interventional

Growth Hormone Treatment of Children With HIV-Associated Growth Failure

NCT00006143
View directory record Official record
Conditions
HIV Infections
Interventions
Somatropin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 13 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 21, 2026, 11:43 PM EDT
Terminated No phase listed Observational Results available

A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device

NCT01243892
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
NuSpin, Somatropin
Device · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
2 Years to 14 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Jul 21, 2026, 11:43 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly

NCT01410799
View directory record Official record
Conditions
Hormone Deficiency, Aging
Interventions
Growth Hormone Releasing Hormone (GHRH )
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Jul 21, 2026, 11:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women

NCT01186796
View directory record Official record
Conditions
Healthy
Interventions
Fulvestrant
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Jul 21, 2026, 11:43 PM EDT
Completed Not applicable Interventional Results available

Single Low-Dose of Supplement Amino Acid

NCT01540773
View directory record Official record
Conditions
Growth Hormone, Amino Acid
Interventions
Amino acid supplement, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 21, 2018 · Synced Jul 21, 2026, 11:43 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

NCT05171855
View directory record Official record
Conditions
Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 81 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Torrance, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 11:43 PM EDT
Terminated No phase listed Observational

A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

NCT05894876
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
No treatment is given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 11 Years
Enrollment
43 participants
Timeline
2024 – 2025
U.S. locations
2
States / cities
Orange, California • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 21, 2026, 11:43 PM EDT
Completed Phase 4 Interventional Results available

Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia

NCT00140413
View directory record Official record
Conditions
Growth Hormone Deficiency, Septo-Optic Dysplasia, Hypopituitarism
Interventions
Nutropin AQ
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 5 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Jul 21, 2026, 11:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Supplementation Trial on Arginine With Metabolic Profiling

NCT03409380
View directory record Official record
Conditions
Protein, Amino Acid, Arginine
Interventions
Arginine Drink, Plain Drink
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Jul 21, 2026, 11:43 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism

NCT00206375
View directory record Official record
Conditions
Hypothyroidism
Interventions
Growth hormone, Growth hormone treatment and puberty
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Jul 21, 2026, 11:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy

NCT00711061
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Jul 21, 2026, 11:43 PM EDT
Recruiting Phase 3 Interventional

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851
View directory record Official record
Conditions
Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions
Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
2 Years to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Palo Alto, California • Sacramento, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 11:43 PM EDT
Terminated Phase 3 Interventional

Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly

NCT01295060
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Jul 21, 2026, 11:43 PM EDT
Completed Phase 4 Interventional Results available

Easypod United States User Trial

NCT00689260
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
easypod
Device
Lead sponsor
EMD Serono
Industry
Eligibility
10 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Jul 21, 2026, 11:43 PM EDT
Completed No phase listed Observational

Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)

NCT02005198
View directory record Official record
Conditions
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
23 Years to 79 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Jul 21, 2026, 11:43 PM EDT
Recruiting No phase listed Observational

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

NCT05820672
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
No intervention
Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
27
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 21, 2026, 11:43 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effects of GH and Lirglutide on AgRP

NCT05681299
View directory record Official record
Conditions
Healthy, Growth Hormone Deficiency
Interventions
growth hormone and lirglutide, growth hormone, liraglutide, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 21, 2026, 11:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

NCT01775358
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
ALRN-5281 0.015 mg/kg, ALRN-5281 0.05 mg/kg, ALRN-5281 0.15 mg/kg, Placebo 0.015 mg/kg, Placebo 0.05mg/kg, Placebo 0.15mg/kg
Drug
Lead sponsor
Aileron Therapeutics, Inc.
Industry
Eligibility
20 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Jul 21, 2026, 11:43 PM EDT
Completed No phase listed Observational

National Cooperative Growth Study in CKD

NCT00616278
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
1 Day to 18 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 21, 2026, 11:43 PM EDT
Terminated Not applicable Interventional Results available

Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

NCT00145704
View directory record Official record
Conditions
Osteopenia
Interventions
bisphosphonate therapy (risedronate), Vitamin D supplement, Calcium
Drug · Dietary Supplement
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Jul 21, 2026, 11:43 PM EDT
Terminated Phase 3 Interventional

Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)

NCT02410356
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
TV-1106, dGH
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Artesia, California • Fountain Valley, California • Lakewood, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Jul 21, 2026, 11:43 PM EDT
Terminated Phase 3 Interventional

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

NCT03145831
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Somavaratan
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
3 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Jul 21, 2026, 11:43 PM EDT